Ascensia Diabetes Care
Explore this company’s associated devices, FDA decisions and regulatory history.

Ascensia Diabetes Care
- Regulatory records
- 1
- Linked recall entries
- 0
- Headquarters
- Not reported
- Brand website
- Not reported
What the linked records show
MedtechLedger currently links 1 FDA record to the applicant name Ascensia Diabetes Care. The collection includes 1 510(k) clearance. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Aug 27, 2026 to Aug 27, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NBW appears in 1 of the 1 linked filings. The collection spans 1 FDA product code. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
Applicant mailing address recorded by FDA: 100 Summit Lake Dr., Valhalla, NY, 10595, US. Recorded on K260545, decision dated Aug 27, 2026.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
Regulatory record history
CONTOUR PLUS BLUE Blood Glucose Monitoring System; CONTOUR NEXT GEN Blood Glucose Monitoring System; CONTOUR NEXT ONE Blood Glucose Monitoring System
K260545 · 510(k) clearance
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.